SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-17-009314
Filing Date
2017-08-31
Accepted
2017-08-31 08:00:25
Documents
6
Period of Report
2017-08-31

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER f6k083017_biondvaxpharma.htm 6-K 19838
2 PRESS RELEASE ON FINANCIAL RESULTS FOR THE PERIOD ENDED JUNE 30, 2017, DATED AUG f6k083017ex99-1_biondvax.htm EX-99.1 269052
3 BIONDVAX PHARMACEUTICALS LTD. UNAUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDE f6k083017ex99-2_biondvax.htm EX-99.2 581693
4 PRESS RELEASE ON DELISTING AND APPOINTMENT OF A COMMITTEE, DATED AUGUST 31, 2017 f6k083017ex99-3_biondvax.htm EX-99.3 13438
5 GRAPHIC ex99-1_001.jpg GRAPHIC 15707
6 GRAPHIC ex99-3_001.jpg GRAPHIC 15707
  Complete submission text file 0001213900-17-009314.txt   928560
Mailing Address 14 EINSTEIN ST. NES-ZIONA L3 74036
Business Address 14 EINSTEIN ST. NES-ZIONA L3 74036 972-8-9302529
BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1213
Type: 6-K | Act: 34 | File No.: 001-37353 | Film No.: 171062069
SIC: 2836 Biological Products, (No Diagnostic Substances)